|
|
Michael Henson, Michael R. Henson has founded or served as CEO and chairman/Board member for 16 emerging healthcare (medical device or biotechnology) firms. Six of these were privately held firms acquired by multinational companies, while five have advanced through the initial public offering (IPO) stage. Several of these companies remain closely held private firms. In total, these firms have received financial investments of approximately $1 billion and have employed in excess of 1,000 people. In addition, Mr. Henson is a member of the Board of Directors of the Cardiovascular Research Foundation (CRF), one of the largest clinical cardiovascular research foundations in the United States. Mr. Henson also serves as principal Manager for four private investment funds and as an advisor to two additional private investment funds, all focused on early and mid - stage medical device startup ventures. |
|
|
Donald Rohrbaugh, Don Rohrbaugh is a seasoned medical device executive with over 30 years experience in both the corporate and start-up environment. He has been the founding CEO of several medical device companies (public, private, US and international) with both venture and public capital raising experience. He has been a consultant and board member for various private and public companies. Corporate experience include 20 years as either a division general manager or research/ development vice president within Baxter Heathcare International. Other diverse experience includes strategic/ business planning, international market development, outsourced manufacturing and international clinical trials. Broad device experience includes implantable pacemakers, diagnostic catheters, patient monitoring systems, drug delivery systems and implantable heart failure devices. Don holds MS degree from the University of Southern California in mechanical engineering. |
|
|
Samuel Shaolian, Mr. Shaolian is an experienced executive with over 25 years of experience leading various medical device companies. He was a founder and President of Vertelink Corporation, a company that developed a pioneering minimally invasive spinal surgery that was acquired by Medtronic, Inc. in November 2003. After the acquisition of Vertelink by Medtronic, Mr. Shaolian co-founded Micardia Corporation, developing novel approaches in the field of dynamic cardiovascular implants. Mr. Shaolian is a co-founder and board member of Onset Medical Corp. and Ellipse Technologies, Inc. Ellipse is developing breakthrough approaches for the treatment of GERD, obesity, and spine. Earlier in his career, he held executive positions as Vice President of R&D at Endologix, Inc. and Cardiodyne, Inc. He holds a Bachelor's degree in Mechanical Engineering as well as a Masters degree in Bio-Medical Engineering from Tel-Aviv University, Israel. Mr. Shaolian is inventor or co-inventor of over 100 issued or pending U.S. patents. |
|
|
Maurice Buchbinder, M.D., After graduating medical school from McGill University in Montreal, Canada, Dr. Buchbinder moved to Stanford University where he began his fellowship training in cardiovascular medicine, helping to pioneer the field of interventional cardiology. He has been involved in the development of many devices now used routinely in the practice of interventional medicine. His interest for many years has focused on improving the treatment and outcomes in patients with coronary artery disease. More recently, Dr. Buchbinder began a series of innovations in the percutaneous treatment of various valve conditions, looking for effective alternatives to the more invasive open heart surgery. Dr. Buchbinder has been the founder of many successful start-up companies. He has served on the scientific advisory boards of several companies. He brings to MiCardia a unique set of skills and clinical experience along with a deep understanding of the economics in medical start-ups. |
|
|
Thomas Thaler, Thomas Thaler graduated from the Swiss Federal Institute of Technology Zürich (ETHZ) in biochemistry and holds a Ph.D. in life sciences. In addition, he has earned an MBA from ETHZ. He has more than 15 years of experience in the biotech and medical technology industry, holding senior management positions with Sulzer Medica/Sulzer Orthopedics (Manager Applied Research, responsible for R&D in biomaterial science, biomechanics and biological science, for reconstructive, trauma, spinal and cardiovascular implants), Schneider Europe (Director Clinical and Regulatory Affairs, responsible for clinical research / development and registration of minimally invasive cardio-vascular devices) and Boston Scientific. In April 2000 he joined Bank Julius Baer as a medical technology and healthcare services equity analyst responsible for global healthcare investment recommendations. Beginning in 2006 he joined HBM Partners, one of the world’s largest investment advisory groups in the field of human medicine, biotechnology and medical technology, as an Investment Advisor for private and public equity investments in medical technology companies. |
